XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Other asset impairments, restructuring and other items [1] $ 673 $ 110
Operating income (loss) [1] (218) (13)
Income (loss) before income taxes [1] (467) (272)
Income taxes (benefit) (52) (19)
Net income (loss) (419) (253)
Net income (loss) attributable to Teva $ (139) $ (220)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic $ (0.12) $ (0.2)
Diluted $ (0.12) $ (0.2)
As previously reported [Member]    
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Other asset impairments, restructuring and other items   $ 96
Operating income (loss)   2
Income (loss) before income taxes   (258)
Income taxes (benefit)   (19)
Net income (loss)   (238)
Net income (loss) attributable to Teva   $ (205)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic   $ (0.18)
Diluted   $ (0.18)
Adjustment [Member]    
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Other asset impairments, restructuring and other items   $ 15
Operating income (loss)   (15)
Income (loss) before income taxes   (15)
Net income (loss)   (15)
Net income (loss) attributable to Teva   $ (15)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic   $ (0.02)
Diluted   $ (0.02)
[1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.